Those that have the herpes virus (HSV-1), (HSV-2), Human Papillomavirus (HPV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV), and in many cases the Hepatitis C virus (HCV), can breathe a little easier. Why?The journal Pharmacology & Pharmacy, in a unique edition on advances in antiviral drugs, published research that established that an all-natural product called Gene-Eden-VIR safely and effectively reduces viral symptoms connected to the viruses mentioned above.
The research was published on August 12, 2013. According to the study, researchers wrote that Gene-Eden-VIR reduced symptoms like genital warts, low and high grade cervical dysplasia, abnormal Pap smear results) and general symptoms (fever blisters, cold sores, hives, skin tabs, panic attacks, depression, kidney problems, sleeping problems, liver problems, fever, fatigue, sore throat, swollen lymph nodes, diarrhea, and even losing weight.
The study is very interesting since it is a first of its kind. Basically, it is a clinical study that used the identical controls required by the FDA for drug testing. This is as opposed to many organizations that sell natural products and don’t do any kind of clinical testing. The developer of Gene-Eden-VIR, incidentally, is a company called polyDNA. They develop and market natural, antiviral products based on a scientific theory put forth by Dr. Hanan Polansky. That theory is called “Microcompetition with Foreign DNA.” The theory explains how foreign DNA fragments, and specifically, DNA of latent viruses, can cause most major diseases.
Additionally it is interesting how Gene-Eden-VIR was developed. The study said that this natural product was formulated by analyzing thousands of scientific papers with a psycho-linguistic software program called simply enough: “Computer Intuition.” The idea behind the program is fairly simple. Every future event is preceded by hints, and the key to predicting these future events is recognizing their significance. Since this computer program successfully predicted the results of the clinical study, it can (and probably should) be used by other biotech and pharmaceutical companies within their R&D efforts.
After all, having an accurate predictor of clinical results would be an amazing benefit to these companies. It could potentially save hundreds of thousands of dollars, and could be a great boon to companies struggling with an R&D productivity crisis.
At the end of the day, however, the real, incredible importance of this study is that it gives doctors and other healthcare practitioners’ confidence in recommending Gene-Eden-VIR to patients being affected by HSV, HPV, EBV, CMV, and HCV. It’s well-known that most of the FDA approved drugs against these viruses have uncomfortable side effects.
As the study authors wrote, “…healthcare practitioners should recommend Gene-Eden-VIR as a safe and efficient antiviral treatment to individuals who have contracted these viruses.”
Find out more about Gene-Eden-VIR.
